Kirby Jessica J, Shaikh Sajid, Bryant David P, Ho Amy F, d'Etienne James P, Schrader Chet D, Wang Hao
Department of Emergency Medicine, JPS Health Network, 1500 S. Main St., Fort Worth, TX 76104, USA.
These authors contributed equally to this article.
J Clin Med Res. 2021 Apr;13(4):237-244. doi: 10.14740/jocmr4476. Epub 2021 Apr 27.
Patients with coronavirus disease 2019 (COVID-19) have shown a range of clinical outcomes. Previous studies have reported that patient comorbidities are predictive of worse clinical outcomes, especially when patients have multiple chronic diseases. We aim to: 1) derive a simplified comorbidity evaluation and determine its accuracy of predicting clinical outcomes (i.e., hospital admission, intensive care unit (ICU) admission, ventilation, and in-hospital mortality); and 2) determine its performance accuracy in comparison to well-established comorbidity indexes.
This was a single-center retrospective observational study. We enrolled all emergency department (ED) patients with COVID-19 from March 1, 2020, to December 31, 2020. A simplified comorbidity evaluation (COVID-related high-risk chronic condition (CCC)) was derived to predict different clinical outcomes using multivariate logistic regressions. In addition, chronic diseases included in the Charlson Comorbidity Index (CCI) and Elixhauser Comorbidity Index (ECI) were scored, and its accuracy of predicting COVID-19 clinical outcomes was also compared with the CCC.
Data were retrieved from 90,549 ED patient visits during the study period, among which 3,864 patients were COVID-19 positive. Forty-seven point nine percent (1,851/3,864) were admitted to the hospital, 9.4% (364) patients were admitted to the ICU, 6.2% (238) received invasive mechanical ventilation, and 4.6% (177) patients died in the hospital. The CCC evaluation correlated well with the four studied clinical outcomes. The adjusted odds ratios of predicting in-hospital death from CCC was 2.84 (95% confidence interval (CI): 1.81 - 4.45, P < 0.001). C-statistics of CCC predicting in-hospital all-cause mortality was 0.73 (0.69 - 0.76), similar to those of the CCI's (0.72) and ECI's (0.71, P = 0.0513).
CCC can accurately predict clinical outcomes among patients with COVID-19. Its performance accuracies for such predictions are not inferior to those of the CCI or ECI's.
2019冠状病毒病(COVID-19)患者呈现出一系列临床结局。既往研究报告称,患者的合并症可预测更差的临床结局,尤其是当患者患有多种慢性病时。我们旨在:1)得出一种简化的合并症评估方法,并确定其预测临床结局(即住院、重症监护病房(ICU)收治、机械通气和院内死亡)的准确性;2)与成熟的合并症指数相比,确定其预测性能的准确性。
这是一项单中心回顾性观察研究。我们纳入了2020年3月1日至2020年12月31日期间急诊科所有COVID-19患者。通过多因素逻辑回归得出一种简化的合并症评估方法(COVID相关高危慢性病(CCC)),以预测不同的临床结局。此外,对纳入Charlson合并症指数(CCI)和Elixhauser合并症指数(ECI)的慢性病进行评分,并将其预测COVID-19临床结局的准确性也与CCC进行比较。
在研究期间从90549次急诊科患者就诊中检索到数据,其中3864例患者COVID-19检测呈阳性。47.9%(1851/3864)的患者住院,9.4%(364例)患者入住ICU,6.2%(238例)接受有创机械通气,4.6%(177例)患者在医院死亡。CCC评估与所研究的四种临床结局相关性良好。CCC预测院内死亡的调整比值比为2.84(95%置信区间(CI):1.81 - 4.45,P < 0.001)。CCC预测院内全因死亡率的C统计量为0.73(0.69 - 0.76),与CCI的(0.72)和ECI的(0.71,P = 0.0513)相似。
CCC能够准确预测COVID-19患者的临床结局。其在这类预测中的性能准确性不低于CCI或ECI。